Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.
| dc.contributor.author | Gupta, Ashish O | |
| dc.contributor.author | Jan Boelens, Jaap | |
| dc.contributor.author | Ebens, Christen L | |
| dc.contributor.author | Kurtzberg, Joanne | |
| dc.contributor.author | Lund, Troy C | |
| dc.contributor.author | Smith, Angela R | |
| dc.contributor.author | Wagner, John E | |
| dc.contributor.author | Wynn, Robert | |
| dc.contributor.author | Blazar, Bruce R | |
| dc.contributor.author | Orchard, Paul J | |
| dc.date.accessioned | 2022-03-23T13:29:34Z | |
| dc.date.available | 2022-03-23T13:29:34Z | |
| dc.date.issued | 2021-06 | |
| dc.date.updated | 2022-03-23T13:29:34Z | |
| dc.description.abstract | Hematopoietic stem cell transplantation (HCT) has been increasingly used for patients with inherited metabolic disorders (IMD). Immune mediated cytopenias (IMCs) after HCT, manifesting as hemolytic anemia, thrombocytopenia, and/or neutropenia, are recognized as a significant complication in this patient population, yet our understanding of the incidence, risk factors, and pathophysiology is currently limited. Review of the published literature demonstrates a higher incidence in younger patients who undergo HCT for a nonmalignant disease indication. However, a few reports suggest that the incidence is even higher among those with IMD (incidence ranging from 10 to 56%). This review summarizes the literature, provides an approach to better understanding of the possible etiology of IMCs, and proposes a diagnostic and management plan for patients with IMD who develop single or multi-lineage cytopenias after HCT. | |
| dc.identifier | 10.1038/s41409-020-01179-5 | |
| dc.identifier.issn | 0268-3369 | |
| dc.identifier.issn | 1476-5365 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | Bone marrow transplantation | |
| dc.relation.isversionof | 10.1038/s41409-020-01179-5 | |
| dc.subject | Humans | |
| dc.subject | Thrombocytopenia | |
| dc.subject | Metabolic Diseases | |
| dc.subject | Transplantation Conditioning | |
| dc.subject | Hematopoietic Stem Cell Transplantation | |
| dc.subject | Consensus | |
| dc.title | Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Kurtzberg, Joanne|0000-0002-3370-0703 | |
| pubs.begin-page | 1238 | |
| pubs.end-page | 1247 | |
| pubs.issue | 6 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Pathology | |
| pubs.organisational-group | Pediatrics | |
| pubs.organisational-group | Duke Cancer Institute | |
| pubs.organisational-group | Institutes and Provost's Academic Units | |
| pubs.organisational-group | Initiatives | |
| pubs.organisational-group | Duke Innovation & Entrepreneurship | |
| pubs.organisational-group | Pediatrics, Transplant and Cellular Therapy | |
| pubs.publication-status | Published | |
| pubs.volume | 56 |